"10.1371_journal.pone.0111412","plos one","2014-10-28T00:00:00Z","Michael W Calik; David W Carley","Center for Narcolepsy, Sleep and Health Research, University of Illinois at Chicago, Chicago, Illinois, United States of America; Department of Biobehavioral Health Science, University of Illinois at Chicago, Chicago, Illinois, United States of America; Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America","Conceived and designed the experiments: MWC DWC. Performed the experiments: MWC. Analyzed the data: MWC. Contributed reagents/materials/analysis tools: DWC. Contributed to the writing of the manuscript: MWC DWC.","The authors have the following interests: David W. Carley owns stocks or shares (Cortex Pharmaceuticals); patents and patent applications assigned to the University of Illinois at Chicago (US 8,207,230 ‚ÄúFunctional role for cannabinoids in autonomic stability during sleep‚Äù, US 8,076,315 ‚ÄúPharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists‚Äù, US 8,053,413 ‚ÄúMethods for treating sleep disorders by cholecystokinin (CCK) receptor B antagonists‚Äù, US 7,705,039 ‚ÄúMethod for treating sleep apnea‚Äù, US 7,160,898 ‚ÄúPharmacological treatment for sleep apnea‚Äù, US 6,974,814 ‚ÄúNeuropharmacological treatment of sleep-related breathing disorders‚Äù, US 6,727,242 ‚ÄúPharmacological treatment for sleep apnea‚Äù, US 6,555,564 ‚ÄúNeuropharmacological treatments of sleep-related breathing disorders‚Äù, US 6,331,536 ‚ÄúPharmacological treatment for sleep apnea‚Äù, US 8,775,340 ‚ÄúDetection and prediction of physiological events in people with sleep disordered breathing using a LAMSTAR neural network‚Äù, US 20140045755 ‚ÄúMETHODS FOR TREATING SLEEP DISORDERS BY CHOLECYSTOKININ (CCK) RECEPTOR B ANTAGONISTS‚Äù, US 20120108570 ‚ÄúPharmacological Treatment for Sleep Apnea‚Äù, US 20120010198 ‚ÄúMethods for Treating Sleep Disorders by Cholecystokinin (CCK) Receptor B Antagonists‚Äù US 20100137251 ‚ÄúFunctional Role for Cannabinoids in Autonomic Stability During Sleep‚Äù, US 20090221658 ‚ÄúPharmacological Treatment for Sleep Apnea‚Äù, US 20090005357 ‚ÄúPharmacological Treatment for Sleep Apnea‚Äù, US 20080261922 ‚ÄúPharmacological Treatments for Sleep Disorders (Apnoe) With Prostanoid Receptor Antagonists‚Äù, US 20080200367 ‚ÄúCompositions and Methods for Treating Sleep Disorders‚Äù, US 20070123517 ‚ÄúPharmacological treatment for sleep apnea‚Äù, US 20060241164 ‚ÄúPharmacological treatment for sleep apnea‚Äù, US 20040127572 ‚ÄúFunctional role for cannabinoids in autonomic stability during sleep‚Äù, US 20030236228 ‚ÄúNeuropharmacological treatment of sleep-related breathing disorders‚Äù, US 20030130266 ‚ÄúPharmacological treatment for sleep apnea‚Äù, US 20020086870 ‚ÄúPharmacological treatment for sleep apnea‚Äù, US 20110251985 ‚ÄúDetection and Prediction of Physiological Events in People with Sleep Disordered Breathing Using a LAMSTAR Neural Network‚Äù, US 20120231083 ‚ÄúSUSTAINED RELEASE CANNABINOID MEDICAMENTS‚Äù, ES 2423412 ‚ÄúComposiciones y m√©todos para tratar los trastornos del sue√±o‚Äù, JP 2010168404 ‚ÄúPHARMACOLOGICAL TREATMENT OF SLEEP APNEA SYNDROME‚Äù, JP 2010059195 ‚Äú PHARMACEUTICAL AGENT WITH SEROTONIN-RELATED ACTIVITY FOR TREATMENT FOR SLEEP APNEA‚Äù, EP 1898921 ‚Äú COMPOSITIONS AND METHODS FOR TREATING SLEEP DISORDERS‚Äù, EP 1868602 ‚Äú PHARMACOLOGICAL TREATMENT FOR SLEEP APNEA‚Äù, WO WO/2007/047575 ‚ÄúPHARMACOLOGICAL TREATMENTS FOR SLEEP-RELATED BREATHING DISORDERS‚Äù, WO WO/2007/047372 ‚Äú PHARMACOLOGICAL TREATMENTS FOR SLEEP DISORDERS (APNOEA) WITH PROSTANOID RECEPTOR ANTAGONISTS‚Äù, WO WO/2007/047577 ‚ÄúUSE OF CALCITONIN-RELATED PEPTIDE (CGRP) ANTAGONISTS OR RELEASE INHIBITORS FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS‚Äù, ES 2267253 ‚ÄúAGENTES CON ACTIVIDAD RELACIONADA CON LA SEROTONINA PARA EL TRATAMIENTO DE LA APNEA DEL SUE√O‚Äù, WO WO/2006/133197 ‚ÄúCOMPOSITIONS AND METHODS FOR TREATING SLEEP DISORDERS‚Äù, WO WO/2006/113448 ‚ÄúPHARMACOLOGICAL TREATMENT FOR SLEEP APNEA‚Äù, CA 2603920 ‚ÄúPHARMACOLOGICAL TREATMENT FOR SLEEP APNEA‚Äù, MX PA/a/2005/004448 ‚ÄúUSE OF SEROTONIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA‚Äù, CN 1708302 ‚ÄúPharmacological treatment for sleep apnea‚Äù, BR PI0315846 ‚ÄúTratamento farmacol√≥gico para apn√©ia do sono‚Äù, EP 1572202 ‚Äú USE OF SEROTONIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA‚Äù, WO WO/2004/041272 ‚ÄúUSE OF SEROTONIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA‚Äù, CA 2503718 ‚ÄúUSE OF SEROTONIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA‚Äù, EP 1372638 ‚ÄúCANNABINOIDS FOR THE TREATMENT OF BREATHING DISORDERS DURING SLEEP‚Äù, WO WO/2002/080903 ‚ÄúFUNCTIONAL ROLE FOR CANNABINOIDS IN AUTONOMIC STABILITY DURING SLEEP‚Äù, CA 2443105 ‚ÄúFUNCTIONAL ROLE FOR CANNABINOIDS IN AUTONOMIC STABILITY DURING SLEEP‚Äù, EP 1066036 ‚ÄúAGENTS WITH SEROTONIN-RELATED ACTIVITY FOR THE TREATMENT FOR SLEEP APNEA‚Äù, WO WO/2000/051590 ‚Äú NEUROPHARMACOLOGICAL TREATMENT OF SLEEP-RELATED BREATHING DISORDERS‚Äù, WO WO/1999/043319 ‚Äú AGENTS WITH SEROTONIN-RELATED ACTIVITY FOR THE TREATMENT FOR SLEEP APNEA‚Äù, CA 2321900 ‚ÄúAGENTS WITH SEROTONIN-RELATED ACTIVITY FOR THE TREATMENT FOR SLEEP APNEA‚Äù, WO WO/2012/068516 ‚Äú LOW DOSE CANNABINOID MEDICAMENTS‚Äù, WO WO/2011/063164 ‚Äú SUSTAINED RELEASE CANNABINOID MEDICAMENTS‚Äù, WO WO/2010/080405 ‚ÄúDETECTION AND PREDICTION OF PHYSIOLOGICAL EVENTS IN PEOPLE WITH SLEEP DISORDERED BREATHING USING A LAMSTAR NEURAL NETWORK‚Äù); completed (not current) research grants from commercial organizations (Glaxo-Wellcome ‚ÄúEffects of adenosine A1 receptor agonists on sleep apnea‚Äù 03/96 ‚Ä 11/96, Glaxo-Wellcome ‚ÄúA single center, randomized double-blind, placebo controlled, two period crossover study to investigate the efficacy of intravenous GR79236 in patients with sleep apnea‚Äù 11/98 ‚Ä 10/99, Synthelabo Research ‚ÄúEffects of serotonin antagonists on sleep apneas in rats‚Äù 4/99 ‚Ä 9/99, Organon Pharmaceutical ‚ÄúA proof of concept trial for Remeron in sleep apnea syndrome‚Äù 12/99 ‚Ä 12/01, BTG International ‚ÄúPharmacologic treatment of sleep apnea‚Äù 04/04 ‚Ä 03/06, BTG International ‚ÄúPharmacologic treatment for sleep apnea (clinical pilot), 10/05 ‚Ä 09/07, Organon Pharmaceutical ‚ÄúA randomized, double-blind, placebo-controlled, multicenter, parallel-group dose ranging clinical trial to assess the efficacy and safety of Org4419-2 in the treatment of obstructive sleep apnea/hypopnea syndrome‚Äù 09/05 ‚Ä 09/06, SteadySleep Rx ‚ÄúRandomized, double-blind, placebo controlled study of the safety and efficacy of Marinol in patients with sleep apnea‚Äù 10/08 ‚Ä 10/12). This does not alter the authors‚Äô adherence to PLOS ONE policies on sharing data and materials.","2014","10","Michael W Calik","MWC",2,TRUE,2,1,1,NA,TRUE,TRUE,FALSE,0,NA,FALSE
